Insulin icodec: an insulin analogue suited for once-weekly dosing in type 2 diabetes - Media Centre | EASD
Prediction: This Could Be This Company's Next Billion-Dollar Product | Nasdaq
Novo Nordisk reaches primary endpoint in phase III of once-weekly insulin — MedWatch
Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment | NEJM
Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Administration in Humans | Journal of Medicinal Chemistry
Novo Nordisk gains GLP-1 market share within and outside the US despite seeing new GLP-1 prescriptions curbed by COVID-19 - MidgardFinance.com
Novo Nordisk bolstered by another late-stage trial of once weekly insulin icodec (NVO) | Seeking Alpha
Novo Nordisk achieve headline results with icodec insulin | pharmaphorum
Novo Nordisk poised to fire on all new GLP1 cylinders following the fourth quarter of 2019, but shares fairly valued - MidgardFinance.com
Insulin Icodec - the once a week long acting insulin from Novo Nordisk | Diabettech - Diabetes and Technology
Novo Nordisk's insulin icodec beats other insulin therapies in diabetes study | S&P Global Market Intelligence
Insulin Icodec - the once a week long acting insulin from Novo Nordisk | Diabettech - Diabetes and Technology
Novo Nordisk once weekly insulin icodec bests Tresiba in lowering blood sugar (NYSE:NVO) | Seeking Alpha
Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment | NEJM
Rationale and design of the phase 3a development programme (ONWARDS 1–6 trials) investigating once‐weekly insulin icodec in diabetes - Philis‐Tsimikas - Diabetes, Obesity and Metabolism - Wiley Online Library
Once-weekly basal insulin icodec: Looking ONWARDS from pharmacology to clinical trials - ScienceDirect
Novo Nordisk Once-Weekly Insulin Comparable to Daily Injections - Type 2 Nation
Insulin icodec: an insulin analogue suited for once-weekly dosing in type 2 diabetes - Media Centre | EASD
Novo Nordisk once-weekly insulin icodec beats Tresiba, matches Sanofi's Lantus in trials | Seeking Alpha
Novo Nordisk's once-weekly insulin hits goals in phase 3 trials
Once-weekly icodec demonstrates superior reduction in HbA1c vs degludec
